18Dec 2018

VALVULOPATHIE CARDIAQUE SEVERE SECONDAIRE A LA CABERGOLINE REVERSIBLE APRES L\'ARRET DU MEDICAMENT :A PROPOS DUN CAS.

  • Serviced?endocrinologie, diabetologie , maladies metaboliques et nutrition,laboratoirepcim, fmpm. Universite cadi ayad. CHUMohamed VI. Marrakech.
Crossref Cited-by Linking logo

  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Nous rapportons lecasd\'unepatiente de 34 ans consultant pour un ad?nomehypophysaire de 2,2 cm en contact avec le chiasmaoptique. La patiente a ?t?trait?avec 1 mg / semaine de Cabergoline (agonistedopaminergique DA) et a d?velopp?unevalvulopathietricuspidestade III qui a ensuite?t?r?versible apr?s l\'arr?t du traitementpar la Cabergoline .

  1. Drake WM, Stiles CE, Howlett TA, et al. :?A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.?J ClinEndocrinolMetab.?2014;99(1):90?6 10.1210/jc.2013-2254
  2. Auriemma RS, Pivonello R, Perone Y, et al. :?Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.?Eur J Endocrinol.2013;169(3):359?366 10.1530/EJE-13-0231
  3. Boguszewski CL, dos Santos CM, Sakamoto KS, et al. :?A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.?Pituitary.?2012;15(1):44?49 10.1007/s11102-011-0339-7
  4. Nachtigall LB, Valassi E, Lo J, et al. :?Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.?ClinEndocrinol (Oxf).?2010;72(1):53?58 10.1111/j.1365-2265.2009.03608.x
  5. Elenkova A, Shabani R, Kalinov K, et al. :?Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.?Eur J Endocrinol.?2012;167(1):17?25 10.1530/EJE-12-0121
  6. Valassi E, Klibanski A, Biller BM:?Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.?J ClinEndocrinol Metab.2010;95(3):1025?1033 10.1210/jc.2009-2095
  7. Peralta C, Wolf E, Alber H, et al. :?Valvular heart disease in Parkinson\'s disease vs. controls: An echocardiographic study.?MovDisord.?2006;21(8):1109?1113 10.1002/mds.20887
  8. Bogazzi F, Buralli S, Manetti L, et al. :?Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.?Int J ClinPract.?2008;62(12):1864?1869 10.1111/j.1742-1241.2008.01779.x
  9. Melmed S, Casanueva FF, Hoffman AR, et al. :?Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.?J ClinEndocrinolMetab.?2011;96(2):273?288 10.1210/jc.2010-1
  10. Schade R, Andersohn F, Suissa S, et al. :?Dopamine agonists and the risk of cardiac-valve regurgitation.?N Engl J Med.?2007;356(1):29?38 10.1056/NEJMoa062222
  11. Bhattacharyya S, Schapira AH, Mikhailidis DP, et al. :?Drug-induced fibrotic valvular heart disease.?Lancet.?2009;374(9689):577?585 10.1016/S0140-6736(09)60252-X
  12. Mast ST, Jollis JG, Ryan T, et al. :?The progression of fenfluramine-associated valvular heart disease assessed by echocardiography.?Ann Intern Med.?2001;134(4):261?266 10.7326/0003-4819-134-4-200102200-00008
  13. Pinero A, Marcos-Alberca P, Fortes J:?Cabergoline-related severe restrictive mitral regurgitation.?N Engl J Med.?2005;353(18):1976?1977 10.1056/NEJM200511033531822
  14. Zanettini R, Antonini A, Gatto G, et al. :?Valvular heart disease and the use of dopamine agonists for Parkinson\'s disease.?N Engl J Med.?2007;356(1):39?46 10.1056/NEJMoa054830
  15. Lancellotti P, Livadariu E, Markov M, et al. :?Cabergoline and the risk of valvular lesions in endocrine disease.?Eur J Endocrinol.?2008;159(1):1?5 10.1530/EJE-08-0213
  16. Droogmans S, Roosens B, Cosyns B, et al. :?Dose dependency and reversibility of serotonin-induced valvular heart disease in rats.?CardiovascToxicol.?2009;9(3):134?141 10.1007/s12012-009-9046-2
  17. Jahnichen S, Horowski R, Pertz HH:?Agonism at 5?HT2B receptors is not a class effect of the ergolines.?Eur J Pharmacol.?2005;513(3):225?228 10.1016/j.ejphar.2005.03.010
  18. Serratrice J, Disdier P, Habib G, et al. :?Fibrotic valvular heart disease subsequent to bromocriptine treatment.?Cardiol Rev.?2002;10(6):334?336
  19. Ruzicka E, Linkova H, Penicka M, et al. :?Low incidence of restrictive valvulopathy in patients with Parkinson\'s disease on moderate dose of pergolide.?J Neurol.2007;254(11):1575?1578 10.1007/s00415-007-0592-x
  20. Colao A, Galderisi M, Di Sarno A, et al. :?Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.?J ClinEndocrinolMetab.?2008;93(10):3777?3784 10.1210/jc.2007-1403
  21. Vallette S, Serri K, Rivera J, et al. :?Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.?Pituitary.?2009;12(3):153?157 10.1007/s11102-008-0134-2
  22. Tan LC, Ng KK, Au WL, et al. :?Bromocriptine use and the risk of valvular heart disease.?MovDisord.?2009;24(3):344?349 10.1002/mds.22228
  23. Van Camp G, Flamez A, Cosyns B, et al. :?Treatment of Parkinson\'s disease with pergolide and relation to restrictive valvular heart disease.?Lancet.2004;363(9416):1179?1183 10.1016/S0140-6736(04)15945-X.

[H. Moata, g. El mghari and n.el Ansari. (2018); VALVULOPATHIE CARDIAQUE SEVERE SECONDAIRE A LA CABERGOLINE REVERSIBLE APRES L\'ARRET DU MEDICAMENT :A PROPOS DUN CAS. Int. J. of Adv. Res. 6 (Dec). 900-903] (ISSN 2320-5407). www.journalijar.com

hanane moata
doctor

DOI:

Article DOI: 10.21474/IJAR01/8214      
DOI URL: https://dx.doi.org/10.21474/IJAR01/8214

Download Full Paper

Download PDF No. of Downloads: 10 | No. of Views: 56